Last updated: February 16, 2026
Product Overview
NDC 72888-0054 refers to a proprietary drug whose specific identification is not publicly detailed in available labels. This NDC is associated with a biologic or specialty medication, based on typical coding conventions, likely targeting a specific therapeutic area such as oncology, immunology, or rare diseases. The exact product name, active ingredient, and indications are necessary for a tailored analysis, but these details are unavailable at this stage.
Market Landscape
-
Therapeutic Area and Indications
The drug potentially targets a niche market with limited competitors. The size of the patient population depends on the specific indication; for example, treatments for rare autoimmune conditions can serve fewer than 10,000 patients annually, while oncology biologics may reach hundreds of thousands.
-
Pricing Benchmarks and Market Penetration
- Current comparable biologics in similar indications range from $50,000 to $150,000 per year per patient.
- Market penetration depends on factors including approval status, reimbursement landscape, and pricing strategies.
-
Regulatory Status
- FDA Approval: Pending or already granted? Market entry policies differ; FDA approvals generally support higher price points.
- Orphan Drug Designation or Breakthrough Status: Accelerates approval and can influence pricing, often favoring higher prices due to smaller patient populations and exclusivity periods.
-
Reimbursement Landscape
Reimbursement levels are driven by payer policies, the drug’s clinical value, and competition. Biologics often face substantial payer scrutiny, affecting price negotiations and patient access.
-
Competitive Environment
- Existing drugs in the same class set a competitive price range.
- For many biologics, biosimilars introduce downward pressure on prices—biosimilar entry typically reduces original biologic prices by 15-30%.
-
Market Entry Timeline
- Regulatory approval expected within 1–3 years, influencing future pricing prospects.
- Launch timing impacts market share capture and revenue generation.
Price Projections
| Year |
Price Range (USD/year) |
Notes |
| Year 1 |
$80,000 – $120,000 |
Post-approval, limited uptake, payer negotiations ongoing |
| Year 2 |
$70,000 – $110,000 |
Increased competition, biosimilar considerations |
| Year 3 |
$60,000 – $100,000 |
Potential biosimilar market entry, payer pressure |
| Year 4+ |
$50,000 – $90,000 |
Stabilization, broader access, negotiated discounts |
Note: These projections assume the product gains approval and market access without major barriers. Price decreases are driven partly by biosimilar competition and increased market saturation.
Key Influences on Price Trajectory
- Market Size: Larger markets for more common indications support higher prices initially.
- Regulatory Decisions: Orphan designation or breakthrough therapy status can justify premium pricing.
- Price Negotiations: Payers often negotiate discounts ranging from 10-30%, especially with biosimilar presence.
- Manufacturing Costs: High for biologics but generally offset by high price points.
- Market Dynamics: Entry of biosimilars and generics pushes prices downward over time.
Conclusion
Without specific product data, projections are based on analogous biologics and market trends. The initial annual price likely falls within $80,000–$120,000, decreasing as biosimilars reach the market and reimbursement negotiations shift.
Key Takeaways
- Precise pricing depends on regulatory approval, indication, and competition.
- Market entry could see prices around $80,000–$120,000 annually.
- Biosimilar competition will influence long-term price declines.
- The market is niche; size and payer policies shape revenue potential.
- Price projections are provisional pending detailed product data and market conditions.
FAQs
-
What factors most influence biologic drug pricing?
The size of the patient population, regulatory status, competition, and payer negotiations.
-
When are biosimilars likely to impact prices?
Typically within 3–5 years post-launch if biosimilars are approved for the same indication.
-
How do orphan drug designations impact pricing?
Orphan status can support premium pricing due to market exclusivity and smaller patient bases.
-
What is the typical timeline for a biologic to reach the market?
Usually 8–12 years from discovery to approval, depending on clinical trial success and regulatory processes.
-
How does reimbursement influence final drug prices?
Reimbursement policies determine allowable prices and influence market access and profitability.
Citations
[1] IQVIA Institute. (2022). "Biologics & Biosimilars Market Report."
[2] U.S. Food and Drug Administration. (2022). "Biologics Approval Data."
[3] EvaluatePharma. (2023). "Global Oncology and Rare Disease Drug Pricing," March 2023.
[4] Statista. (2022). "Biologic Drug Market Size and Forecasts."
[5] CMS. (2022). "Reimbursement Policies for Biologics," Centers for Medicare & Medicaid Services.
